Inari Medical, a minimally-invasive medical device maker for venous diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company's minimally invasive devices have been used to treat over 6,700 patients in 500 hospitals, 90% of which have been since the company's broader commercial launch in the third quarter 2018.
The Irvine, CA-based company was founded in 2011 and booked $51 million in sales for the 12 months ended December 31, 2019. It plans to list on the Nasdaq under the symbol NARI. BofA Securities, Morgan Stanley, Canaccord Genuity and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
The article High-growth medical device maker Inari Medical files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
